Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (" Aurinia " or the " Company ") is pleased to announce that the eight incumbent directors of the Company were elected at the Company's annual general meeting (the " Meeting ") held on June 7, 2021.
Detailed results of the vote by proxy for the election of directors are provided below:
Votes For (%)
Votes Withheld (%)
George M. Milne
David R.W. Jayne
Joseph P. Hagan
Daniel G. Billen
R. Hector MacKay-Dunn
Timothy P. Walbert
In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved . Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com .
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company's head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.